Nanjing Vazyme Biotech Gets egulatory Nod for Key Neurological Disease Test Kits

marketscreener
2025.09.25 06:50
portai
I'm PortAI, I can summarize articles.

(MT Newswires) -- Nanjing Vazyme Biotech (SHA:688105) obtained medical device registration certificates in China for seven diagnostic reagent kits focused on neurological diseases. The newly approved products include biomarkers for Alzheimer's disease and Parkinson's disease, according to a Thursday filing with the Shanghai bourse. The certificates are valid until Sept. 22, 2030.

Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.